Biomarker testing has evolved as one of the most transformative and dynamic areas of clinical diagnostics. It continues to revolutionize the healthcare industry created applications related to the treatment of a gamut of infectious diseases. Analysts at BIS Research expect the global infectious disease biomarker testing market to grow at a robust rate in the future.
As per a recent study published on medRxiv, the preprint server for health sciences, reportes that D-dimer, a biomarker can be used in predicting the mortality risk caused by COVID-19. D-dimer is a fragment of the protein that is produced fibrin clots break up. Typically, these clots are linked to each other. D-dimer is a biomarker of great importance, especially in the case of suspected thromboembolism (VTE).
In addition, based on the recent study spearheaded by Professor Galit Alter from Harvard Medical School and Associate Professor Helen Chu at the University of Washington School of Medicine highlights that the SARS-CoV-2 consists of two main proteins, i.e., Spike (S) protein and the nucleocapsid (N) protein. The study of the humoral immune response in recovered patients and immunodominance in deceased patients enabled them to identify biomarkers that can act as indicators to improve the chance of survival of patients in the case of COVID-19.
According to the premium market intelligence published by BIS Research, the global infectious disease biomarker testing market is projected to witness market growth of 14.48% during the forecast period of 2020-2030. The growth is attributed to the increasing prevalence of infectious diseases, advancement in the biomarker testing platform with enhanced speed and better patient safety compliance, and significant improvement in the funding scenario.
For instance, recently, to obtain the MTPConnect Biomedical Translational Bridging (BTB) project funding project, SpeeDx Pty. Ltd., an innovative molecular diagnostic solution developer based out of Sydney, collaborated with researchers at Nepean Hospital in Nepean Blue Mountains Regional Health District (NBMLHD) in Australia.
However, as per the insights shared by the analysts at BIS Research, certain factors, including poorly suited reimbursement policies, high capital investments and lack of intricate testing centers, and uncertain regulatory framework delaying test approvals, are also restraining the growth of the market.
The market has been segmented on the basis of product, application, technology, pathogen, end-user, and region. The product segment is further categorized into assays and platforms. The application segment of the market is further categorized into respiratory infection, sexually transmitted infection, bloodstream and hospital-acquired infection, urinary tract infection, gastro-intestinal infection, gastro-intestinal infection, and others. Also, the end-user segment of the market is further segmented into hospitals and clinics, diagnostic centers, research laboratories, and other end users.
Further, several key are relentlessly working in the field of biomarker testing. These include F. Hoffmann-La Roche Ltd, Qiagen N.V., Siemens Healthineers AG, Beckman Coulter, Inc., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific Inc, and bioMérieux SA, among others.
